Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | C1R | P00736 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34461705 | 0.85 | ADORA2A (0.46) | ADORA2ACFTRTP53ALDH1A1HSD11B1 | |
| SCHEMBL34461745 | 0.82 | ADORA2A (0.41) | ADORA2ACFTRALDH1A1HSD11B1MAPT | |
| SCHEMBL34461787 | 0.82 | ADORA2A (0.42) | ADORA2ACFTRTP53ALDH1A1HSD11B1 | |
| SCHEMBL34461757 | 0.81 | ADORA2A (0.62) | ADORA2ATP53ALDH1A1MAPTADORA3 | |
| SCHEMBL34461750 | 0.74 | ADORA2A (0.38) | ADORA2AALDH1A1NPSR1ADORA3ADORA2B | |
| SCHEMBL34461736 | 0.72 | MEN1 (0.40) | ADORA2AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL34461729 | 0.70 | ALDH1A1 (0.35) | ADORA2AALDH1A1ADORA3ADORA2BEGFR | |
| SCHEMBL4259212 | 0.65 | MPO (0.62) | — | |
| SCHEMBL34461760 | 0.64 | GRIA1 (0.32) | CFTRALDH1A1MEN1KMT2A | |
| SCHEMBL34461751 | 0.63 | MPO (0.42) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | ADORA2A 586/4885CFTR 1523/4885TP53 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.